

Dinutuximab beta for treating neuroblastoma

Information for the public

Published: 22 August 2018

www.nice.org.uk

Dinutuximab beta (Qarziba) is available on the NHS. It is a possible treatment for high-risk neuroblastoma in people who are at least 12 months old if:

- their disease has at least partly responded to induction chemotherapy
- they have had high-dose chemotherapy and a stem cell transplant and
- they have not had treatment with an anti-GD2 immunotherapy drug.

If the person is not eligible for dinutuximab beta but is already taking it, they should be able to continue until they (or their parent or carer) and their doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Cancer Research UK](#), 0808 800 4040
- [Children's Cancer and Leukaemia Group](#), 0116 252 5858
- [Macmillan Cancer Support](#), 0808 808 0000
- [Neuroblastoma UK](#), 0208 940 4353
- [Solving Kids' Cancer](#), 0207 284 0800

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3069-2